December 3, 2014 | Teva Pharmaceutical Industries launched a generic equivalent of its Exforge HCT tablets in the United States, a treatment for high blood pressure. Teva was the first company to file for the generic version, and the product will be eligible for 180 days of marketing exclusivity. Exforge HCT is marketed by Novartis Pharmaceuticals and saw annual sales of $158 million in the US. Teva was founded in 1901 by Eli Hurvitz and is headquartered in the US.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments